L. Wenning

发表

A dynamic model of ex vivo granulopoiesis

E. Papoutsakis, W. Miller, D. Hevehan, 2000 .

Modeling pO(2) distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models.

W M Miller, E. Papoutsakis, W. Miller, 2001, Biophysical journal.

Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme

I. Mcintosh, J. Wagner, K. Lasseter, 2007, Drug Metabolism and Disposition.

Lack of a Pharmacokinetic Effect of Raltegravir on Midazolam: In Vitro/In Vivo Correlation

P. Lu, J. Wagner, M. Troyer, 2008, Journal of clinical pharmacology.

Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans.

D. Connolly, J. Paolini, J. Wagner, 2008, Journal of clinical lipidology.

Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment

F. Liu, R. Preston, G. Garrett, 2018, European Journal of Drug Metabolism and Pharmacokinetics.

Effects of multiple doses of clarithromycin on the pharmacokinetics of laropiprant in healthy subjects.

J. Wagner, P. Jumes, J. Schwartz, 2011, Cardiovascular therapeutics.

Magnesium sulfate pharmacokinetics after intramuscular dosing in women with preeclampsia

B. Carvalho, O. Oladapo, H. Witjes, 2021, AJOG global reports.

Effect of Low‐, Moderate‐, and High‐Fat Meals on Raltegravir Pharmacokinetics

J. Chodakewitz, J. Wagner, D. Brainard, 2011, Journal of clinical pharmacology.

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

J. Mallolas, S. Pol, A. Howe, 2013, The Lancet. Infectious diseases.

Pharmacokinetic-pharmacodynamic studies of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects.

J. Wagner, S. Ramael, K. Gottesdiener, 2013, British journal of clinical pharmacology.

Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids.

R. Murphy, L. Wenning, 1999, Biotechnology and bioengineering.

Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics

J. Wagner, K. Lasseter, R. Robson, 2009, Antimicrobial Agents and Chemotherapy.

Effects of omeprazole on plasma levels of raltegravir.

H. Teppler, J. Wagner, B. Nguyen, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Lack of a Significant Drug Interaction between Raltegravir and Tenofovir

H. Teppler, J. Wagner, K. Lasseter, 2008, Antimicrobial Agents and Chemotherapy.

Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir

H. Greenberg, J. Wagner, K. Gottesdiener, 2008, Antimicrobial Agents and Chemotherapy.

Suppression of Niacin‐induced Vasodilation with an Antagonist to Prostaglandin D2 Receptor Subtype 1

G. O'neill, F. Liu, I. de Lepeleire, 2007, Clinical pharmacology and therapeutics.

Pharmacokinetics of Raltegravir in Individuals With UGT1A1 Polymorphisms

T. Rushmore, H. Greenberg, E. Carlini, 2009, Clinical pharmacology and therapeutics.

Pharmacokinetics of Laropiprant and Glucuronide Metabolite in Patients with Severe Renal Insufficiency

J. Wagner, J. Stone, M. Stroh, 2009, American journal of therapeutics.

Exposure–response characterisation of tildrakizumab in chronic plaque psoriasis: Pooled analysis of 3 randomised controlled trials

T. Kerbusch, Petra M Jauslin, L. Wenning, 2020, British journal of clinical pharmacology.

Raltegravir Thorough QT/QTc Study: A Single Supratherapeutic Dose of Raltegravir Does Not Prolong the QTcF Interval

J. Wagner, T. Marbury, K. Gottesdiener, 2008, Journal of clinical pharmacology.

Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment

Pratik Bhagunde, J. Butterton, D. Panebianco, 2019, European Journal of Clinical Pharmacology.

Clinical Pharmacology Profile of Boceprevir, a Hepatitis C Virus NS3 Protease Inhibitor: Focus on Drug–Drug Interactions

J. Butterton, L. Wenning, Hwa-ping Feng, 2015, Clinical Pharmacokinetics.

Pharmacokinetics, Pharmacodynamics, and Safety of a Prostaglandin D2 Receptor Antagonist

G. O'neill, F. Liu, H. Greenberg, 2008, Clinical pharmacology and therapeutics.

Pharmacokinetics, Pharmacodynamics, and Safety of a Prostaglandin D 2 Receptor

H. Greenberg, K. Metters, J. Wagner, 2007 .

Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV‐infected children 4 weeks to 18 years of age

H. Teppler, E. Acosta, M. Rizk, 2015, Journal of clinical pharmacology.

A Pharmacokinetic Comparison of Adult and Paediatric Formulations of Raltegravir in Healthy Adults

M. Rizk, J. Wagner, Elizabeth G. Rhee, 2014, Antiviral therapy.

Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.

S. Spector, H. Teppler, E. Acosta, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.

K. Mounzer, K. Squires, L. Bekker, 2013, AIDS research and human retroviruses.

Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients

J. Eron, M. Rizk, J. Zhao, 2012, Antimicrobial Agents and Chemotherapy.

Clinical Pharmacology Profile of Raltegravir, an HIV‐1 Integrase Strand Transfer Inhibitor

J. Wagner, D. Brainard, J. Stone, 2011, Journal of clinical pharmacology.

Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir

J. Wagner, K. Gottesdiener, J. Stone, 2009, Antimicrobial Agents and Chemotherapy.

Absorption, Metabolism, and Excretion of [14C]MK-0524, a Prostaglandin D2 Receptor Antagonist, in Humans

G. Garrett, G. Doss, R. Desai, 2007, Drug Metabolism and Disposition.

Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects

J. Wagner, K. Lasseter, S. Ramael, 2008, Clinical pharmacology and therapeutics.

RECEPTOR ANTAGONIST, IN HUMANS

G. Garrett, G. Doss, R. Desai, 2007 .

Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

W. Bridson, J. Wagner, K. Gottesdiener, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The effect of MK-0524, a prostaglandin D2 receptor antagonist, on prostaglandin D2-induced nasal airway obstruction in healthy volunteers

P. Deutsch, K. Gottesdiener, K. Mazina, 2007, European Journal of Clinical Pharmacology.

Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1.

G. O'neill, F. Liu, J. Wagner, 2007, Clinical pharmacology and therapeutics.

Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis

F. Gheyas, P. Armstrong, R. Blaustein, 2022, Clinical pharmacology and therapeutics.

803 RELATIONSHIP BETWEEN TRANSAMINASE LEVELS AND PLASMA PHARMACOKINETICS FOLLOWING ADMINISTRATION OF MK-5172 WITH PEGYLATED INTERFERON alfa-2b AND RIBAVIRIN (PR) TO HCV GENOTYPE (G) 1 TREATMENT-NAÏVE PATIENTS

M. Cooreman, L. Wenning, N. Mobashery, 2013 .

Physiologically Based Pharmacokinetic Modeling of Doravirine and Its Major Metabolite to Support Dose Adjustment With Rifabutin

Yang Liu, K. Yee, Tamara D. Cabalu, 2020, Journal of clinical pharmacology.

Fine‐Needle Aspiration for the Evaluation of Hepatic Pharmacokinetics of Vaniprevir: A Randomized Trial in Patients With Hepatitis C Virus Infection

N. Shire, R. Railkar, A. Webber, 2019, Clinical pharmacology and therapeutics.

Population Pharmacokinetics of Doravirine and Exposure-Response Analysis in Individuals with HIV-1

K. Yee, L. Wenning, R. de Greef, 2019, Antimicrobial Agents and Chemotherapy.

Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor

P. Angus, E. Gane, T. Marbury, 2017, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of Famotidine in Infants

G. Kearns, D. Panebianco, J. Blumer, 2005, Clinical pharmacokinetics.

Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS.

E. Woolf, B. Matuszewski, L. Wenning, 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals

C. Kovacs, D. Cooper, R. Steigbigel, 2006, Journal of acquired immune deficiency syndromes.

Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of a 48-Week Controlled Study

C. Crumpacker, C. Kovacs, H. Teppler, 2007, Journal of acquired immune deficiency syndromes.

Influence of cellular trafficking on protein synthesis inhibition of immunotoxins directed against the transferrin receptor.

P. Yazdi, R. Murphy, L. Wenning, 1995, Cancer research.

Emerging pharmacology: inhibitors of human immunodeficiency virus integration.

Larissa Wenning, D. Hazuda, M. Iwamoto, 2009, Annual review of pharmacology and toxicology.

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.

C. Katlama, P. Sax, Y. Yazdanpanah, 2017, The lancet. HIV.

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.

Jing Zhao, Christine Katlama, Benjamin Young, 2011, The Lancet. Infectious diseases.

Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir

J. Chodakewitz, J. Wagner, T. Marbury, 2009, Antimicrobial Agents and Chemotherapy.

Quantitative analysis of protein synthesis inhibition and recovery in CRM107 immunotoxin-treated HeLa cells.

P. Yazdi, R. Murphy, L. Wenning, 1998, Biotechnology and bioengineering.

Maternal–Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

H. Teppler, E. Acosta, S. Nachman, 2019, CPT: pharmacometrics & systems pharmacology.

Raltegravir In Vitro Effect on Bilirubin Binding

D. Stevenson, R. Wong, M. Mirochnick, 2013, The Pediatric infectious disease journal.

Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir (RAL) in Phase III Studies in Treatment Experienced HIV-Infected Patients Following 48 Weeks of Treatment

L. Wenning, 2008 .

Leveraging model-informed approaches for drug discovery and development in the cardiovascular space

Manash S. Chatterjee, Ferdous Gheyas, Marissa F Dockendorf, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

A comparison of the pharmacokinetics of two different formulations of extended-release niacin

J. Paolini, J. Wagner, L. Wenning, 2009 .

Ultrasensitive liquid chromatography-tandem mass spectrometric methodologies for quantification of five HIV-1 integrase inhibitors in plasma for a microdose clinical trial.

Sheila Breidinger, Eric J Woolf, Larissa Wenning, 2012, Analytical chemistry.

ICH M9 Guideline in development on Biopharmaceutics Classification System-based biowaivers: An Industrial Perspective from the IQ Consortium.

Yunhui Wu, David Lindley, Manish Gupta, 2019, Molecular pharmaceutics.

Effect of Raltegravir on the Pharmacokinetics of Methadone

J. Wagner, W. Hanley, M. Iwamoto, 2010, Journal of clinical pharmacology.

Modeling pO(2) distributions in the bone marrow hematopoietic compartment. I. Krogh's model.

W M Miller, E. Papoutsakis, W. Miller, 2001, Biophysical journal.

Alternative Magnesium Sulfate Dosing Regimens for Women With Preeclampsia: A Population Pharmacokinetic Exposure‐Response Modeling and Simulation Study

P. Lumbiganon, L. Duley, B. Carvalho, 2019, Journal of clinical pharmacology.

Population Pharmacokinetic Modeling to Evaluate Standard Magnesium Sulfate Treatments and Alternative Dosing Regimens for Women With Preeclampsia

P. Lumbiganon, L. Duley, B. Carvalho, 2018, Journal of clinical pharmacology.

Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis

T. Kerbusch, Suresh Vatakuti, P. Kulkarni, 2019, Clinical Pharmacokinetics.

Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects

J. Wagner, J. Stone, T. Kakuda, 2008, Antimicrobial Agents and Chemotherapy.

Effects of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Steady‐State Pharmacokinetics of Digoxin in Healthy Adult Subjects

J. Wagner, A. Johnson‐Levonas, L. Wenning, 2010, Journal of clinical pharmacology.

Lack of a Clinically Meaningful Pharmacokinetic Effect of Rifabutin on Raltegravir: In Vitro/In Vivo Correlation

J. Lunceford, N. Hariparsad, J. Wagner, 2011, Journal of clinical pharmacology.

An Extended Point-Area Deconvolution Approach for Assessing Drug Input Rates

Daniel J. Holder, Kuang C. Yeh, Gregory A. Winchell, 2001, Pharmaceutical Research.

Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug–Drug Interactions

K. Yee, R. Sanchez, S. Stoch, 2020, Clinical Drug Investigation.

Dynamic model of ex vivo granulocytic kinetics to examine the effects of oxygen tension, pH, and interleukin-3.

W M Miller, E. Papoutsakis, W. Miller, 2000, Experimental hematology.

Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment

J. Butterton, D. Panebianco, M. Iwamoto, 2019, European Journal of Clinical Pharmacology.

Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women.

J. Wagner, J. Stone, W. Hanley, 2011, British journal of clinical pharmacology.

Emerging Pharmacology: Inhibitors of Human

D. Hazuda, M. Iwamoto, L. Wenning, 2009 .

Clinical Pharmacology Worldwide: A Global Health Perspective

A. Ali, G. Pillai, L. Wenning, 2021, Clinical pharmacology and therapeutics.

Raltegravir: the first HIV‐1 integrase strand transfer inhibitor in the HIV armamentarium

D. Hazuda, R. Leavitt, H. Teppler, 2011, Annals of the New York Academy of Sciences.

Effects of Extended-Release Niacin and Extended-Release Niacin/Laropiprant on the Pharmacokinetics of Simvastatin in Healthy Subjects

J. Wagner, P. De Kam, L. Wenning, 2015, American journal of therapeutics.

Lack of a Signiﬁcant Drug Interaction between Raltegravir and Tenofovir (cid:1)

H. Teppler, J. Wagner, K. Lasseter, 2008 .

A Pharmacokinetic Comparison of Adult and Paediatric Formulations of Raltegravir in Healthy Adults

M. Rizk, J. Wagner, Elizabeth G. Rhee, 2014, Antiviral therapy.

Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.

S. Spector, H. Teppler, E. Acosta, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Ultrasensitive liquid chromatography-tandem mass spectrometric methodologies for quantification of five HIV-1 integrase inhibitors in plasma for a microdose clinical trial.

M. Rizk, E. Woolf, Li Sun, 2012, Analytical chemistry.

PDUFA VI: It Is Time to Unleash the Full Potential of Model‐Informed Drug Development

V. Sinha, N. Mehrotra, L. Wenning, 2018, CPT: pharmacometrics & systems pharmacology.